Results 121 to 130 of about 2,198,265 (159)

Improving Long-Term Outcomes in ATTR-CM: Aiming at a Moving Target. [PDF]

JACC CardioOncol
Fine NM.
europepmc   +1 more source

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary. [PDF]

Future Cardiol
Wixner J, Dispenzieri A, Amass L, Carlsson M, Riley S, Powers E, Kelly JW.   +6 more
europepmc   +1 more source

Comparison of in-clinic assessment of 6MWT by conventional method and using wearable sensors for patients with ATTR-CM. [PDF]

Future Cardiol
Soman P, Khouri MG, Lenihan D, Reyentovich A, Sperry BW, Sowalsky K, Bai Y, Du J, Katz L, Siddhanti S, Fox JC.   +10 more
europepmc   +1 more source

Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary. [PDF]

Future Cardiol
Garcia-Pavia P, Kristen AV, Drachman B, Carlsson M, Amass L, Maurer MS, THAOS investigators.   +6 more
europepmc   +1 more source

Protocol of the follow-up of patients with transthyretin amyloid cardiomyopathy by multimodality imaging (FAITH) study: a prospective observational study in patients with ATTR-CM undergoing treatment with tafamidis. [PDF]

BMJ Open
Gröschel J, Barzen G, Zernikow J, Blaszczyk E, Hahn K, Pernice HF, Sack I, Romero Dorta E, van Dijck P, Heidecker B, Schwenke C, Schulz-Menger J, Spethmann S.   +12 more
europepmc   +1 more source

Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. [PDF]

Circulation
Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS.   +25 more
europepmc   +1 more source

Machine Learning of Echocardiographic Left Ventricular Myocardial Radiomics for Identification of Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Elzieny AA, Alreshq R, Ullah I, Fine D, Teruya S, Helmke S, Gallegos C, Miller EJ, Slivnick JA, Maurer MS, Li B, Ruberg FL.   +11 more
europepmc   +1 more source

Survival Outcomes in Transthyretin Cardiac Amyloidosis in the Tafamidis Era: Real-World Evidence from Greece. [PDF]

Diagnostics (Basel)
Kourti FE, Antonopoulos AS, Kytinos V, Tsampras T, Kouroutzoglou A, Kyriakopoulos D, Koilakou ME, Karampina P, Gardikioti V, Terentes-Printzios D, Kasiakogias A, Leontsinis I, Chrysohoou C, Koutelou M, Toutouzas K, Tsioufis K, Vlachopoulos C.   +16 more
europepmc   +1 more source